EVALUATION OF IMMUNOGENICITY IN THE NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY (PASS) FOR THE PROSPECTIVE EVALUATION OF THE SAFETY AND TOLERABILITY PROFILE OF HSA-free SUBCUTANEOUS INTERFERON (scIFN) β-1a IN TREATMENT OF NAàVE RELAPSING MULTIPLE SCLEROSIS (MS) PATIENTS - STEP STUDY